Safety of Extended interval Dosing Immune Checkpoint Inhibitors: a multicentre cohort study.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of the National Cancer Institute"
DOI: 10.1093/jnci/djad061
Abstract: BACKGROUND Real-life spectrum and survival implications of immune-related adverse events (irAEs) in patients treated with extended interval dosing (ED) immune checkpoint inhibitors (ICIs) are unknown. METHODS Characteristics of 812 consecutive solid cancer patients who received… read more here.
Keywords: checkpoint inhibitors; immune checkpoint; interval dosing; dosing immune ... See more keywords